Defence Therapeutics Inc.
DTCFF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $4 | $4 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $9 | $3 | $4 | $2 |
| Sales & Mktg Exp. | $2 | $2 | $3 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $6 | $7 | $3 |
| Operating Income | -$13 | -$6 | -$7 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$13 | -$7 | -$7 | -$3 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$13 | -$7 | -$7 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.17 | -0.2 | -0.11 |
| % Growth | -76.5% | 15% | -81.8% | – |
| EPS Diluted | -0.3 | -0.17 | -0.2 | -0.11 |
| Weighted Avg Shares Out | 45 | 40 | 36 | 27 |
| Weighted Avg Shares Out Dil | 45 | 40 | 36 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $7 | $3 |
| EBITDA | -$13 | -$6 | $0 | $0 |
| % Margin | – | – | – | – |